Affimed price target raised to $25 from $15 at Laidlaw

Laidlaw raised the firm’s price target on Affimed Therapeutics to $25 from $15 and keeps a Buy rating on the shares following the Q1 report. The analyst cites the “much improved outlook” of AFM13 with combination of NK cells as well as other pipeline developments for the target increase. Affimed has again validated the NK engager platform to further advance these programs forward, the analyst tells investors in a research note.